Zhi Tong Cai Jing·2025-08-04 02:27Group 1 - The core point of the news is that Genting New Year (01952) has announced a subscription for 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1][2] - Following the subscription, Genting New Year will hold a total of 15.8462 million ADS and 6.0786 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital after the subscription [1] - I-Mab is a global biotechnology company focused on developing precision immuno-oncology drugs for cancer treatment, with three clinical-stage pipeline products [1] Group 2 - The board believes that the subscription confirms I-Mab's unique capabilities in clinical translation, particularly in the U.S., and complements Genting New Year's strong influence in Asia [2] - The collaboration is expected to create synergies between I-Mab's differentiated 4-1BB technology platform and bispecific antibody development pipeline, enhancing existing investments in mRNA cancer vaccines [2]